Cytokine Signalling Forum

Publications





January 19

Análisis agrupado de la seguridad de Tofacitinib como monoterapia o en combinación con Fármacos Antirreumáticos Modificadores de la Enfermedad Convencionales de base en una Población de Fase 3 con Artritis Reumatoide

Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R.
Semin Arthritis Rheum. 2018 Dec;48(3):406-415. doi: 10.1016/j.semarthrit.2018.07.006.

In this pooled analysis of Phase 3 Tofacitinib (TOF) trials, safety profiles were generally similar between patients receiving monotherapy and combination therapy. Although selected adverse events of interest showed lower incidence rates (IRs) for TOF monotherapy patients. TOF has been studied as monotherapy and in combination with csDMARDs. In this post-hoc analysis, data were pooled from six Phase 3 TOF studies in RA patients to further examine the safety profile when used as monotherapy or i...

Keywords: JAK, Tofacitinib, Clinical, Safety

Translated by: Igor